Clinical Trial Update: Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating individualized voriconazole antifungal therapy has been suspended in immunocompromised patients with Aspergillosis and Fusariosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aspergillosis
• Fusariosis

Drugs mentioned

• VFEND (Voriconazole)

Snippet

Sponsor: Brynn Chappell | Conditions: Immunocompromised Patient, Aspergillosis | Phase 2 | Status: SUSPENDED